作者: Charles S Fuchs , Jiri Tomasek , Cho Jae Yong , Filip Dumitru , Rodolfo Passalacqua
DOI: 10.1016/S0140-6736(13)61719-5
关键词: Clinical trial 、 Internal medicine 、 Hazard ratio 、 Clinical endpoint 、 Adverse effect 、 Surgery 、 Placebo 、 Gastroenterology 、 Medicine 、 Intention-to-treat analysis 、 Randomized controlled trial 、 Ramucirumab
摘要: … We aimed to assess whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, … , to receive best supportive care plus either ramucirumab 8 mg/kg or placebo, intravenously …